Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
821
datasets available to search
ShareScore release 0.9.0
Dataset results
821 results for “anticoagulant”
Catalysis of Tos-Gly-Pro-Arg-p-nitroanilide by α-thrombin in the presence of an anticoagulant produced by D. andersoni (dataset formatted for analysis by interferENZY)
<p><strong>Main description</strong></p> <p>This dataset depicts the catalysis of the chromogenic substrate Tos-Gly-Pro-Arg-p-nitroanilide by α-thrombin in the presence of an anticoagulant produced by <em>Dermacentor andersoni</em>, for fixed concentration of enzyme (and modulator) and variation of concentration of initial substrate. It was originally documented in <em>Biophysical Chemistry 252 (2019) 106193</em> (<a href="https://doi.org/10.1016/j.bpc.2019.106193">https://doi.org/10.1016/j.bpc.2019.106193</a>), and <em>PNAS 116 (28) 13873-13878</em> (<a href="https://doi.org/10.1073/pnas.1905177116">https://doi.org/10.1073/pnas.1905177116</a>), and then used as a study case for the webserver interferENZY (a web-based tool for enzymatic assay validation and standardized kinetic analysis; visit <a href="https://interferenzy.i3s.up.pt">https://interferenzy.i3s.up.pt</a> for more information). To this end, it was converted to the format here presented: tab-separated *.txt input required for interferENZY analysis.</p> <p> </p> <p><strong>Dataset organization</strong></p> <p>Line 1: Tab-separated initial concentrations of substrate Tos-Gly-Pro-Arg-p-nitroanilide in micromolar (µM) concentration</p> <p>Line 2: Concentration of enzyme (0.15 nM)</p> <p>Line 3: Units of time</p> <p>Line 4: Units of concentration for substrate values and measurements</p> <p>Line 5: Dataset name</p> <p>Line 6 and downwards: Tab-separated column-pairs of the progress curves (time,Product) corresponding to the indicated values of initial concentrations of substrate in line 1</p> <p> </p> <p><strong>Contact information:</strong></p> <p>Maria Filipa Pinto (mfpinto@i3s.up.pt)<br> Pedro M. Martins (pmartins@ibmc.up.pt)</p> <p>i3S – Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen, 208, 4200-135 Porto, Portugal. Telephone number: +351 226 074 900</p>
Repository of Raw Datasets for the Study of Anticoagulation and the Incidence of Stroke and Other Outcomes in Patients with Left Ventricular Thrombus
<p>The optimal duration of anticoagulation in patients with left ventricular thrombus (LVT) is unknown. The data package herein presented contains the data used to assess the effect of duration of anticoagulation in the incidence of stroke in patients with left ventricular thrombus (LVT) in a tertiary hospital. These data includes clinical and demographic information, treatment choices (vitamin K antagonists [VKA] versus direct oral anticoagulants [DOAC]), duration of treatment, reason for interruption of treatment, occurrence of stroke, acute myocardial infarction, bleeding events, thrombus resolution and recurrence, and death.<br> The raw dataset is available upon request to the corresponding author.</p>
ASSESSMENT OF ADHERENCE TO NEW ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION PATIENTS WITHIN THE OUTPATIENT REGISTRY PROFILE. PROSPECTIVE OBSERVATIONAL STUDY (ANTEY study)
<p><strong>Rationale</strong></p> <p>Prevention of stroke and thromboembolic complications in non-valvular atrial fibrillation is one of the most common indications for the use of all NOACs and warfarin in cardiology. The issue of regular intake of all OACs, i.e. the issue of adherence to anticoagulation therapy, is paramount for better treatment. The problem of assessment of different aspects of adherence to OACs in patients with atrial fibrillation within an outpatient registry is of current interest.</p> <p><strong>Primary</strong> <strong>Study</strong> <strong>Objectives</strong></p> <p>The aim of the present study is to assess adherence to therapy and factors associated with adherence in patients with CV disease complicated by non-valvular atrial fibrillation requiring OAC treatment within the outpatient registry PROFILE (prospective, observational study).</p> <ol> <li>Data collection in patients with non-valvular atrial fibrillation requiring OAC treatment included in the registry</li> <li>Evaluation of actual patient adherence to OACs</li> </ol> <p><strong>Secondary Study Objective(s)</strong></p> <ol> <li>Evaluation of potential patient adherence to OACs</li> <li>Determination of most significant factors associated with adherence to OACs in patients with non-valvular AF</li> <li>Validation of new original questionnaire</li> <li>Evaluation of doctor’s adherence to OAC prescription according to Guidelines (ESC). Management of atrial fibrillation,2016)</li> </ol> <p><strong>Material and methods</strong></p> <p>.The study included 201 patients with nonvalvular AF from the outpatient "PROFILE" registry, 118 (58,7%) males. The mean age was 71,1 ±8,7 years. The study protocol consisted of the inclusion visit (V0), 6-month follow-up visit (V1), and phone contact 1 year after V0 (follow-up, FU). In V0, all patients were prescribed one of the NOACs. At V1 doctors could recommend warfarin or another NOAC to patients, who have refused to take prescribed NOAC. Medical adherence was determined using the original questionnaire</p> <p><strong>Inclusion Criteria (detailed)</strong></p> <ul> <li>Men and women above 18 years of age who were included in the "PROFILE" registry by the start of the observational study</li> <li>Presence of written informed consent to participate in the study, fill in the study questionnaires, and have personal data analyzed</li> <li>Presence of any form of non-valvular atrial fibrillation with CHA<sub>2</sub>DS<sub>2</sub>-VASc score of ≥1 or patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc score = 0, who are already taking OAK</li> </ul> <p><strong>Exclusion Criteria</strong></p> <p>Patients with high bleeding risk, including patients with:</p> <ul> <li>Congenital or acquired bleeding disorders</li> <li>Uncontrolled resistant hypertension</li> <li>Exacerbation of gastric and duodenal ulcer</li> <li>Vascular retinopathy</li> <li>Recent history of intracranial or intracerebral hemorrhage</li> <li>Pathology of the brain and spinal cord vessels</li> <li>Recent history of the brain, spinal cord, or eye surgery</li> <li>History of bronchiectasis or pulmonary hemorrhage</li> <li>A CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 0 (OACs are not indicated)</li> <li>Pregnancy, lactation</li> <li>Planned surgery</li> <li>Known hypersensitivity to ingredients of medications used in the study</li> </ul> <p><strong>Visit schedule</strong></p> <p>Visit schedule</p> <p>Two visits at 6-month intervals are scheduled for each patient as part of routine clinical practice:</p> <p>Visit 0– visit at study entry:</p> <ul> <li>receiving written informed consent to participate in research from patients</li> <li>inclusion in the program</li> <li>assessment of inclusion and exclusion criteria</li> <li>verification of non-valvular atrial fibrillation diagnosis (according to medical documentation, confirming the history of atrial fibrillation: ECG, Holter monitoring, etc..)</li> <li>collecting information on received medication therapy, including OACs</li> <li>physical examination of patients (measurements of blood pressure, heart rate, height, weight, waist circumference)</li> <li>questioning of patients to determine potential and actual adherence to OACs</li> <li>computation of points on the scale CHA<sub>2</sub>DS<sub>2</sub>-VASc and HAS-BLED to determine the indications for the appointment of the OACs and the identification of an increased risk of bleeding</li> <li>to determine the INR in patients who agreed to replace the use of warfarin with one of the NOACs</li> <li>prescription of OACs according to routine clinical practice and official labels for these medications</li> <li>instructing patients (according to the specifically designed scheme) to regularly take prescribed medications, be aware of precautionary measures when taking OACs, telling them about the pros and cons of treatment with OACs</li> </ul> <p>Visit 1 – visit at 6 months after the Visit 0:</p> <ul> <li>collecting information on patients’ compliance with doctor’s recommendations</li> <li>collecting information on patients’ actual medication therapy</li> <li>collecting information on the safety of treatment with OACs (in case the patient has been taking them), recording all adverse events that occurred during the study period</li> <li>measurements of blood pressure, heart rate as a part of routine clinical practice</li> <li>questioning of patients to determine potential and actual adherence to OACs</li> </ul> <p>FU - follow-up calls to patients (one year)</p> <p>Phone contact to determine patient’s life status, possible (fatal and non-fatal complications of non-valvular atrial fibrillation) and fill (after receiving patient’s consent) the original questionnaire.</p> <p><strong>Primary Outcome</strong></p> <p>The proportion of complete, partial adherent and non-adherent patients according to the original questionnaire</p> <p><strong>Secondary Outcomes </strong></p> <ul> <li>The proportion of potentially adherent patients (according to the original questionnaire)</li> <li>Identification of baseline characteristics associated with adherence</li> <li>The proportion of doctors prescribed OAC according to guidelines.</li> </ul> <p><strong>Safety Outcomes </strong></p> <p>Adverse events and outcomes were recorded from the start of treatment with the OAC until the end of the observational study period. The doctor evaluated the severity of adverse events and outcomes if necessary took measures for their medical treatment according to current clinical practice.</p> <p> </p> <p> </p>
In silico design, docking simulation, and ANN-QSAR model for predicting the anticoagulant activity of thiourea isosteviol compounds as FXa inhibitors
<p>The present work combined molecular modeling and docking approach for searching and designing novel thiourea isosteviol-based compounds as potential FXa inhibitors. Elaborated regression model establishes the relationships between experimentally determined anticoagulant activity and molecular descriptors and enables the prediction of FXa inhibitory activity for novel compounds. The obtained results proved that the Artificial Neural Network algorithm facilitates the search for the most promising isosteviol derivatives incorporating thiourea fragments as FXa inhibitors. Moreover, docking simulation confirms the prominent binding of the newly in silico designed molecules with the active sites of the protein, which may be the lead molecules and can be further optimized for the efficient pharmacodynamic and pharmacokinetic profiles. The enclosed files are representations of molecular structures of thiourea isosteviol compounds with experimentally tested FXa inhibitory activity (i20-i39) geometrically optimized in hyperchem, newly in silico designed thiourea isosteviol compounds geometrically optimized in hyperchem (e1-e11), one file contains molecular descriptors for optimized structures calculated in Dragon and there is also a code for ANN QSAR model for predicting activity of novel thiourea isosteviol compounds. </p>
Can we collect health-related quality of life information from anticoagulated atrial fibrillation participants who have recently experienced a bleed? An observational feasibility study in primary, and secondary care and through an online forum
<p>The purpose of the study was to evaluate the feasibility of recruiting participants diagnosed with atrial fibrillation (AF) taking oral anticoagulation therapies (OACs) and recently experiencing a bleed to collect health-related quality of life (HRQoL) information.</p> <p><strong>Design</strong></p> <p>Observational feasibility study. The study aimed to determine the feasibility of recruiting participants with minor and major bleeds, the most appropriate route for recruitment and the appropriateness of the Patient Reported Outcome Measures (PROMs) selected for collecting HRQoL information in AF patients, and the preferred format of the surveys.</p> <p><strong>Setting</strong></p> <p>Primary care, secondary care, and via an online patient forum.</p> <p><strong>Participants</strong></p> <p>The study population was adult patients (≥ 18) with Atrial Fibrillation (AF) taking oral anticoagulation therapies (OATs) who had experienced a recent major or minor bleed within the last four weeks.</p> <p><strong>Primary and Secondary outcome measures</strong></p> <p>Primary outcome:</p> <p>Patient reported outcome measures (PROMs): EuroQol 5 dimensions-5 levels (EQ-5D-5L); Perception of anticoagulant treatment questionnaire, part 2 only (PACT-Q, part 2); Atrial fibrillation effect on quality of life (AFEQT)</p> <p>Secondary outcomes:</p> <p>Location of bleed; bleed severity; current treatment; patient perceptions of HRQoLin relation to bleeding events.</p> <p><strong>Results</strong></p> <p>We received initial expressions of interest from 103 participants. We subsequently recruited 32 participants to the study- 14 from primary care and 18 through the AF forum. No participants were recruited through secondary care. Despite 32 participants consenting, only 26 initial surveys were completed. We received follow-up surveys from 11 participants (8 primary care and 3 AF forum). COVID-19 had a major impact on the study. </p> <p><strong>Conclusions</strong></p> <p>Primary care was the most successful route for recruitment. Most participants recruited to the study experienced a minor bleed. Further ways to recruit in secondary care should be explored, especially to capture more serious bleeds. </p> <p><strong>Registration</strong></p> <p>The study was adopted onto the NIHR Portfolio (I.D. #47771) and registered with www.ClinicalTrials.gov (#NCT04921176) in February 2021.</p> <p>Dataset contains all anonymised data for the participants who completed the survey including demographics, details of bleeds, co-morbidities and completed patient reported outcomes</p>
Strategies for Anticoagulation During Venovenous ECMO
ClinicalTrials.gov study NCT04997265. IPD Sharing: YES. Countries: 1. Publications: 21.
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
ClinicalTrials.gov study NCT02744092. IPD Sharing: YES. Countries: 1. Publications: 2.
Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation
ClinicalTrials.gov study NCT02608099. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Tranexamic Acid To Reduce Bleeding in Patients Treated With New Oral Anticoagulants Undergoing Dental Extraction
ClinicalTrials.gov study NCT03413891. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban
ClinicalTrials.gov study NCT02220725. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
ClinicalTrials.gov study NCT03061006. IPD Sharing: Not stated. Countries: 1. Publications: 1.
IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation
ClinicalTrials.gov study NCT03259373. IPD Sharing: NO. Countries: 1. Publications: 2.
Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care
ClinicalTrials.gov study NCT04362085. IPD Sharing: NO. Countries: 1. Publications: 5.
Anticoagulants Comparative Benefit-risk Ratio in Real Life
ClinicalTrials.gov study NCT02785354. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
ClinicalTrials.gov study NCT04367831. IPD Sharing: NO. Countries: 1. Publications: 3.
A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation
ClinicalTrials.gov study NCT02047565. IPD Sharing: YES. Countries: 1. Publications: 1.
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
ClinicalTrials.gov study NCT00508924. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Efficacy of a Health Belief Model Based Intervention for Anticoagulation Adherence
ClinicalTrials.gov study NCT03864900. IPD Sharing: NO. Countries: 1. Publications: 3.
Effectiveness of Bridging Anticoagulation for Surgery (The BRIDGE Study)
ClinicalTrials.gov study NCT00786474. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome
ClinicalTrials.gov study NCT00537290. IPD Sharing: NO. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.